TABLE 1.
Patient Demographics
| Category | Microarray Patients n (% of total) | Anti‐Cardiolipin Analysis Patients n (% of total) | aPTT Analysis Patients n (% of total) | Extended APA Testing Patients n (% of total) |
|---|---|---|---|---|
| Total | 11 | 86 | 26 | 22 |
| Subtype | ||||
| Control | 4 (36.4%) | 18 (20.9%) | 11 (42.3%) | 11 (50%) |
| CRSsNP | 0 (0%) | 15 (17.4%) | 0 (0%) | 0 (0%) |
| CRSwNP | 7 (63.6%) | 53 (61.6%) | 15 (57.7%) | 11 (50%) |
| Gender (NS) |
3 Female, 8 Male (27.3% F, 72.7% M) |
34 Female, 52 Male (39.5% F, 60.5% M) |
12 Female, 14 Male (46.2% F, 53.8% M) |
9 Female, 13 Male (40.9% F, 59.1% M) |
| Age (NS) | ||||
| Average | 49.5 (±11.7) years | 46.2 (±14.1) years | 46(±13.8) years | 44.2 (±14.4) years |
| Range | 33–66 years | 21–74 years | 21– 66 years | 21 – 66 years |
| Asthma (NS) | 4 (36.4%) | 28 (32.6%) | 7 (26.9%) | 9 (40.9%) |
| Control | 0 (0%) | 2 (2.3%) | 1 (3.8%) | 2 (9.1%) |
| CRSsNP | N/A | 4 (4.7%) | N/A | N/A |
| CRSwNP | 4 (36.4%) | 22 (25.6%) | 6 (23.1%) | 7 (31.8%) |
| AERD (*p = .03) | 2 (18.2%) | 3 (3.5%) | 0 (0%) | 0 (0%) |
| Revision Surgery (NS) | 2 (18.2%) | 20 (23.5%) | 5 (19.2%) | 4 (18.2%) |
| Control | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| CRSsNP | N/A | 2 (2.3%) | N/A | N/A |
| CRSwNP | 2 (18.2%) | 18 (20.9%) | 5 (19.2%) | 4 (18.2%) |
| Smoking Status (NS) | ||||
| Never | 8 (72.7%) | 66 (76.7%) | 17 (65.4%) | 14 (63.6%) |
| Prior Use | 2 (18.2%) | 18 (20.9%) | 7 (26.9%) | 6 (27.3%) |
| Current | 1 (9.1%) | 2 (2.3%) | 2 (7.7%) | 2 (9.1%) |
| Pre‐Op Steroid Use (NS) | ||||
| Nasal | 1 (9.1%) | 18 (20.9%) | 4 (15.4%) | 4 (18.2%) |
| Inhaled | 0 (0%) | 14 (16.3%) | 2 (7.7%) | 2 (9.1%) |
| Oral | 2 (18.2%) | 13 (15.1%) | 3 (11.5%) | 2 (9.1%) |
| Pre‐Op Antibiotic Use (NS) | 1 (9.1%) | 4 (4.7%) | 1 (3.8%) | 1 (4.5%) |
All demographics are not statistically significant (NS) except for AERD patients which were significantly higher (p = .0308) in the Microarray and Anti‐cardiolipin Analysis groups.